Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Dutton-Regester

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Pigment Cell & Melanoma Research|January 18, 2012
Reviewing the somatic genetics of melanoma: from current to future analytical approachesKen Dutton-Regester, Nicholas K Hayward
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapyKen Dutton-Regester, Nicholas K Hayward
Pigment Cell & Melanoma Research|February 3, 2016
The genomic landscape of cutaneous melanomaTongwu Zhang, Ken Dutton-Regester, Kevin M Brown, et al.
JMIR Serious Games|March 25, 2021
A Virtual Reality Game to Change Sun Protection Behavior and Prevent Cancer: User-Centered Design ApproachCaitlin Horsham, Ken Dutton-Regester, Jodie Antrobus, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2014
BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapyAndrew P Barbour, Yue Hang Tang, Nicola Armour, et al.
Pigment Cell & Melanoma Research|March 26, 2011
Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factorGlen M Boyle, Susan L Woods, Vanessa F Bonazzi, et al.
International Journal of Cancer|April 7, 2020
Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanomaHsin-Yi Tseng, Jan Dreyer, Abdullah Al Emran, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.
Genes, Chromosomes & Cancer|January 18, 2012
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor geneKen Dutton-Regester, Lauren G Aoude, Derek J Nancarrow, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Pigment Cell & Melanoma Research|January 18, 2012
Reviewing the somatic genetics of melanoma: from current to future analytical approachesKen Dutton-Regester, Nicholas K Hayward
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapyKen Dutton-Regester, Nicholas K Hayward
Pigment Cell & Melanoma Research|February 3, 2016
The genomic landscape of cutaneous melanomaTongwu Zhang, Ken Dutton-Regester, Kevin M Brown, et al.
JMIR Serious Games|March 25, 2021
A Virtual Reality Game to Change Sun Protection Behavior and Prevent Cancer: User-Centered Design ApproachCaitlin Horsham, Ken Dutton-Regester, Jodie Antrobus, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2014
BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapyAndrew P Barbour, Yue Hang Tang, Nicola Armour, et al.
Pigment Cell & Melanoma Research|March 26, 2011
Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factorGlen M Boyle, Susan L Woods, Vanessa F Bonazzi, et al.
International Journal of Cancer|April 7, 2020
Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanomaHsin-Yi Tseng, Jan Dreyer, Abdullah Al Emran, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Molecular Cancer Therapeutics|March 3, 2012
A high-throughput panel for identifying clinically relevant mutation profiles in melanomaKen Dutton-Regester, Darryl Irwin, Priscilla Hunt, et al.
Genes, Chromosomes & Cancer|January 18, 2012
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor geneKen Dutton-Regester, Lauren G Aoude, Derek J Nancarrow, et al.
Pageof 3